The VENTANA PD-L1 (SP263) Assay helps determine which patients with non-small cell lung cancer (NSCLC) may be eligible for treatment with Libtayo monotherapy1 based on the results of the Phase III EMPOWER-Lung 1 study.
This additional approval will allow more patients with locally advanced and metastatic NSCLC broader access to the immunotherapy Libtayo.
PD-L1 testing provides clinicians with essential information that helps guide clinical decision making and improve patient outcomes.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.